Genfit S.A. functions as a late-stage biopharmaceutical enterprise, primarily dedicated to the identification and advancement of novel therapeutic drugs and diagnostic technologies for metabolic and liver-related conditions. A prominent candidate in its pipeline is Elafibranor, currently in Phase III clinical trials for treating primary biliary cholangitis. The company is also developing NIS4, a diagnostic platform aimed at identifying nonalcoholic steatohepatitis (NASH) and fibrosis. Its diverse portfolio further includes VS-01, designed for Urea Cycle Disorder (UCD) and Organic Acidemia Disorder (OAD); GNS561, which is undergoing Phase 1b/2a trials for cholangiocarcinoma (CCA); and a combination of VS-01-ACLF with Nitazoxanide (NTZ), in Phase 1 for acute-on-chronic liver failure. Additionally, Genfit is researching VS-02-HE in preclinical stages to reduce hyperammonemia and stabilize blood ammonia, alongside SRT-015, an ASK1 inhibitor engineered to suppress cellular apoptosis, inflammation, and fibrosis. Genfit has established strategic collaborations, notably a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test. It also partnered with Genoscience Pharma to jointly develop and market the experimental treatment GNS561 for CCA. The company was founded in 1999 and is headquartered in Loos, France.
